IDIAPJGol Drives Projects to Improve Atrial Fibrillation Detection and Prevent Stroke

Research in Deltebre develops digital tools and AI for anticoagulant treatment and early arrhythmia detection.

Generic image of a medical device with abstract data visualizations.
AI

Generic image of a medical device with abstract data visualizations.

IDIAPJGol, through its research groups GAVINA and EBRICTUS in Terres de l’Ebre, is developing innovative projects to combat atrial fibrillation, improving anticoagulant treatment and identifying patients at high risk of developing it.

Atrial fibrillation is the most common cardiac arrhythmia and a significant risk factor for ischemic stroke. Often asymptomatic, its early detection and adequate treatment are key to preventing cardiovascular complications.
The GAVINA group is working on FIBRILEX, a clinical decision support software designed to integrate with electronic health records. This tool will help healthcare professionals better manage atrial fibrillation by assessing stroke and bleeding risk, and optimizing anticoagulant treatment through alerts and patient information documents. The first phase of development and validation is complete, and integration and evaluation in a real clinical setting are currently being prepared.
Meanwhile, the EBRICTUS group focuses on the early identification of individuals at risk of developing atrial fibrillation using predictive models, digital monitoring, and artificial intelligence. Projects like AFRICAT validated a predictive model, PREFATE incorporated 14-day heart rhythm monitoring, and MATHIAS uses AI and clinical data to detect risk even before diagnosis.
EBRICTUS's trajectory has been recognized with awards such as the Best Poster Award at the European Stroke Organisation Conference (ESOC 2026) in Maastricht and an accolade from the Institut Català de la Salut. For AF Awareness Week 2026, they have promoted awareness activities on risk factors, warning signs, and the importance of pulse monitoring to prevent stroke, which is projected to affect one in three people over 55.
Based on information from the official source: IDIAP Jordi Gol (20/11/2026)